viewPharmaxis Ltd

Pharmaxis enters trading halt ahead of share placement

The company plans to raise funds by way of a share placement.

capital raising concept with documents and reading glasses
Further details regarding the capital raising are expected by Tuesday

Pharmaxis Ltd (ASX:PXS) has been granted a trading halt by the ASX pending the release of information regarding a share placement.

The company’s shares will remain halted until the earlier of, the release of relevant information, or, the commencement of trading next Tuesday.

READ: Pharmaxis powering ahead with phase I LOXL2 studies

Pharmaxis is an established pharmaceutical research company working on new therapies to treat inflammatory and fibrotic diseases.

This includes liver disease NASH, pulmonary fibrosis, kidney and liver fibrosis, inflammatory bowel diseases and cancer.

The company finished the June quarter with just over $31 million in cash.

Quick facts: Pharmaxis Ltd

Price: 0.076 AUD

Market: ASX
Market Cap: $30.04 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...



Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) CEO Gary Phillips speaks to Proactive's Andrew Scott after it was announced its US licensee Chiesi Farmaceutici SpA filed a resubmission to the FDA for Bronchitol® . The move addresses issues raised by the US Food and Drug Administration (FDA)...

on 6/5/20

2 min read